Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

With clinical trials ongoing, efficient clinical production of adeno-associated virus (AAV) to treat large numbers of patients remains a challenge. We compared distribution of AAV8 packaged with Factor VIII (FVIII) in cell culture media and lysates on days 3, 5, 6, and 7 post-transfection and found increasing viral production through day 6, with the proportion of viral particles in the media increasing from 76% at day 3 to 94% by day 7. Compared to FVIII, AAV8 packaged with Factor IX and Protective Protein/Cathepsin A vectors demonstrated a greater shift from lysate towards media from day 3 to 6, implying that particle distribution is dependent on recombinant vector. Larger-scale productions showed that the ratio of full-to-empty AAV particles is similar in media and lysate, and that AAV harvested on day 6 post-transfection provides equivalent function in mice compared to AAV harvested on day 3. This demonstrates that AAV8 production can be optimized by prolonging the duration of culture post-transfection, and simplified by allowing harvest of media only, with disposal of cells that contain 10% or less of total vector yield. Additionally, the difference in particle distribution with different expression cassettes implies a recombinant vector-dependent processing mechanism which should be taken into account during process development.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813606PMC
http://dx.doi.org/10.1038/mtm.2016.15DOI Listing

Publication Analysis

Top Keywords

distribution aav8
8
culture media
8
dependent recombinant
8
recombinant vector
8
aav8 packaged
8
packaged factor
8
particles media
8
particle distribution
8
aav harvested
8
harvested day
8

Similar Publications

Bietti crystalline dystrophy (BCD) is an autosomal recessive disorder caused by loss-of-function mutations in the gene, characterized by crystal-like lipid deposits in the retina, progressive photoreceptor loss, and retinal pigment epithelium (RPE) deterioration. Currently, there are no approved treatments for BCD. VGR-R01, an investigational gene therapy, uses subretinal administration of recombinant adeno-associated virus type 8 (AAV8) vector to deliver the human CYP4V2 gene.

View Article and Find Full Text PDF

Adeno-associated virus serotype 8 (AAV8) is a widely used gene therapy vector with the characteristics of high transduction efficiency and tissue specificity. Reliable detection of AAV8 is crucial for assessing therapeutic efficacy and tracking its in vivo distribution. Herein, we develop a nanobody-based electrochemiluminescence (ECL) imaging immunosensor based on integrating advanced functional materials with spatially resolved signal output for sensitive and visual detection of AAV8.

View Article and Find Full Text PDF

Barrier Function of the Extracellular Matrix in AAV Gene Therapy.

bioRxiv

August 2025

Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.

Purpose –: The extracellular matrix (ECM) is a major component of the tissue microenvironment which may pose a barrier to the distribution of AAV in target organs, preventing delivery of therapeutic cargo. We sought to address this potential barrier to AAV gene therapy by furthering our understanding of AAV-ECM interactions. We hypothesized that both the AAV serotype and ECM composition will impact AAV transport and gene delivery.

View Article and Find Full Text PDF

The primate cerebral cortex relies on long-range connections to integrate information across spatially distributed and functionally specialized areas, yet tools for selectively modulating these pathways remain limited. Here, we present an optimized intersectional viral and optogenetic strategy for precisely exciting and inhibiting projection-specific neurons in the common marmoset. Building on a mouse-to-marmoset pipeline, we first validated that optogenetic activation of inhibitory neurons (via AAV9-Dlx-ChR2) enables robust local cortical inhibition.

View Article and Find Full Text PDF

Gene therapy for hemophilia B offers the advantage of a single administration with sustained therapeutic effects. This study evaluated the systemic safety, efficacy, biodistribution, and immunogenicity of AAV8-FIX-TripleL, a recombinant adeno-associated virus type 8 (AAV8) vector encoding a modified factor IX (FIX) variant with increased activity. In this good laboratory practice (GLP)-compliant study, 180 male FIX-knockout hemophilia B mice were randomized into 12 groups ( = 15) and received intravenous AAV8-FIX-TripleL at therapeutic (5 × 10 VG/kg) or supraphysiological (5 × 10 VG/kg) doses on Day 1.

View Article and Find Full Text PDF